Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04442230 · ClinicalTrials.gov registry record · Phase 2
NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)
A Phase 2 study, sponsored by Altimmune.
- Terminated
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT04442230 is a Phase 2 study that was terminated before completion, run by Altimmune. The registered enrollment target is 48 participants.
The verdict
NCT04442230, a Phase 2 study, was terminated before completion, sponsored by Altimmune.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of NasoVAX in preventing worsening of symptoms and hospitalization in patients with early COVID-19.
Interventions
- OTHER Placebo
- BIOLOGICAL NasoVAX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2020-10-10 |
| Est. Completion | 2021-02-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04442230
The ClinicalTrials.gov registry entry for NCT04442230 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Altimmune, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04442230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04442230 about?
NCT04442230 is a clinical study titled "NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)". The purpose of this study is to evaluate the safety and effectiveness of NasoVAX in preventing worsening of symptoms and hospitalization in patients with early COVID-19.
What is the current status of trial NCT04442230?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2020-10-10. Estimated completion is 2021-02-15.
What interventions are being tested in trial NCT04442230?
The interventions under investigation include: Placebo (OTHER), NasoVAX (BIOLOGICAL).
Who is sponsoring clinical trial NCT04442230?
This trial is sponsored by Altimmune, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.